Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million.

Business Highlights

  • Idenix announced today that it had successfully completed a proof-of-concept study of its lead HCV antiviral development program, IDX184, a novel once-daily liver-targeted nucleotide prodrug. This double-blind, placebo-controlled, monotherapy, dose-escalation study in HCV genotype-1-infected patients evaluated the safety and antiviral activity of IDX184. For more information on the results of this study, please see the related press release issued today by Idenix.
  • The company continued to advance its two preclinical HCV antiviral programs. Idenix is finalizing IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory filings. The company has synthesized the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic toxicology studies in two species to support regulatory applications.
  • Finally, during the quarter, Idenix streamlined operations with the closure of its screening facility in Cagliari, Italy. This activity is now being performed at the company's laboratory in Cambridge, Massachusetts. As a result, Idenix reduced its workforce by 18 employees and incurred a restructuring charge in the quarter of $1.5 million.

"Our focus this year has been on the advancement of our HCV discovery and development programs, and I am pleased with the progress we have made to date," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "As we work through the second half of the year, we plan to evaluate IDX184 in combination with pegylated interferon and ribavirin in a 14-day dose-ranging study. Additionally, we plan to file investigational new drug applications from our non-nucleoside polymerase inhibitor and protease inhibitor programs. These efforts will take us closer to our ultimate goal of developing novel combinations of direct-acting HCV antivirals."

For the second quarter ended June 30, 2009, Idenix reported total revenues of $2.4 million, compared to total revenues of $1.6 million in the second quarter of 2008. Idenix reported a net loss of $16.3 million, or a loss of $0.28 per basic and diluted share, for the second quarter ended June 30, 2009, compared to a net loss of $18.9 million, or a loss of $0.34 per basic and diluted share for the second quarter ended June 30, 2008.

For the six months ended June 30, 2009, Idenix reported total revenues of $6.5 million, compared to total revenues of $3.6 million for the six months ended June 30, 2008. The company reported a net loss of $29.2 million, or a loss of $0.50 per basic and diluted share, for the six months ended June 30, 2009, compared to a net loss of $39.4 million, or a loss of $0.70 per basic and diluted share, for the six months ended June 30, 2008.

2009 Financial Guidance

The company continues to expect that its current cash, cash equivalents and marketable securities can fund operations through at least the first quarter of 2010. This guidance assumes no milestone payments, additional license fees, reimbursement for development programs and no financing activities.

Conference Call Information

Idenix will hold a conference call and webcast today at 4:30 p.m. ET. To access the call please dial 800-774-5358 U.S./Canada or 706-758-9475 International and enter passcode 20088902 or to listen to a live webcast and view accompanying slides, go to "Calendar of Events" in the Idenix Investor Center at A replay of the call will also be available from 6:30 p.m. ET on July 20, 2009 until August 3, 2009 12:00 a.m. ET. To access the replay, please dial 800-642-1687 U.S./Canada or 706-645-9291 International and enter passcode 20088902. An archived webcast will also be available for two weeks after the call on the Idenix website.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of hepatitis C virus. For further information about Idenix, please refer to

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184 or any other product candidate and any future clinical trials involving our product candidates and expectations with respect to additional milestone payments, future royalty payments, funding of operations and future cash balances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that historical sales of Tyzeka(R)/Sebivo(R) (telbivudine) will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG and GlaxoSmithKline, respectively; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2008 and the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

                           IDENIX PHARMACEUTICALS, INC.


                      (IN THOUSANDS, EXCEPT PER SHARE DATA)


                                  Three Months Ended      Six Months Ended
                                       June 30,               June 30,
                                  ------------------      ----------------
                                   2009        2008       2009        2008
    Revenues:                      ----        ----       ----        ----
      Collaboration revenue -
       related party             $2,182      $1,433     $6,098      $3,478
      Other revenue                 267         159        362         157
                                    ---         ---        ---         ---
        Total revenues            2,449       1,592      6,460       3,635
    Operating expenses(1):
      Cost of revenues              492         415        954         810
      Research and
       development               11,400      14,136     22,250      29,004
      General and
       administrative             5,357       6,651     11,373      14,972
      Restructuring charges       1,506          37      1,506         297
                                  -----          --      -----         ---
        Total operating
         expenses                18,755      21,239     36,083      45,083
                                 ------      ------     ------      ------
    Loss from operations        (16,306)    (19,647)   (29,623)    (41,448)
    Other income(expense), net     (249)        485       (297)      1,425
                                  -----         ---      -----       -----
    Loss before income taxes    (16,555)    (19,162)   (29,920)    (40,023)
    Income tax benefit              241         256        679         657
                                    ---         ---        ---         ---
    Net loss                   $(16,314)   $(18,906)  $(29,241)   $(39,366)
                               =========   =========  =========   =========
    Basic and diluted net
     loss per share:             ($0.28)     ($0.34)    ($0.50)     ($0.70)
                                 =======     =======    =======     =======
    Shares used in calculation
     of basic and diluted net
     loss per share:             59,077      56,359     58,014      56,316
                                 ======      ======     ======      ======
    (1) Share-based compensation
     expenses included in
     operating expenses
     amounted to approximately:

      Research and development     $408        $467       $847      $1,127
      General and administrative    783         876      1,599       1,755

                           IDENIX PHARMACEUTICALS, INC.


                                  (IN THOUSANDS)


                                              June 30,     December 31,
                                                2009           2008
    ASSETS                                      ----           ----
    Cash and cash equivalents                 $50,128       $41,509
    Marketable securities                          --         1,424
    Receivables from related party                843           894
    Other current assets                        3,729         6,214
                                                -----         -----
        Total current assets                   54,700        50,041
    Intangible asset, net                      11,806        12,387
    Property and equipment, net                11,367        13,238
    Marketable securities                       1,584         3,145
    Other assets                                3,335           969
                                                -----           ---
        Total assets                          $82,792       $79,780
                                              =======       =======

    Accounts payable and accrued expenses     $12,608       $13,136
    Deferred revenue, related party             6,110         5,965
    Other current liabilities                   1,617           475
                                                -----           ---
        Total current liabilities              20,335        19,576
    Long-term obligations                      33,411        17,061
    Deferred revenue, related party,
     net of current portion                    33,607        35,790
                                               ------        ------
        Total liabilities                      87,353        72,427
    Stockholders' equity (deficit)             (4,561)        7,353
                                               ------         -----
        Total liabilities and stockholders'
         equity (deficit)                      $82,792      $79,780
                                               =======      =======

    Idenix Pharmaceuticals' Contacts:
    Media: Teri Dahlman (617) 995-9905
    Investors: Amy Sullivan (617) 995-9838

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... 2015.  --> Paris , qui ... DERMALOG, le leader de l,innovation biométrique, a inventé ... passeports et empreintes sur la même surface de balayage. ... et l,autre pour les empreintes digitales. Désormais, un seul ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):